For the second quarter of 2020, Thermo Fisher reported revenue growth of 10% to reach $6.92 billion, compared with $6.32 billion in the same quarter of 2019.

Compared with revenue in the first quarter of 2020 ($6.23 billion), ending on March 28, the company had revenue growth of 11% in the most recent quarter.

The company reported $1.3 billion of COVID-19-related revenue, and Thermo Fisher attributed much of the success in the second quarter to quickly mobilizing resources to support global COVID-19 responses.

Thermo Fisher expands COVID-19 therapies, vaccines
Thermo Fisher Scientific is expanding the development and production of COVID-19 vaccines, therapies, and additional treatments.

Thermo Fisher to develop, manufacture next-gen immunotherapy
Thermo Fisher Scientific has formed a strategic partnership with PharmAbcine for the development and manufacturing of PMC-309, a next-generation immune...

Thermo Fisher to operate new CSL biologics facility
Thermo Fisher Scientific has entered into a long-term lease agreement with CSL to operate a new biologics manufacturing facility in Lengnau, Switzerland.

Thermo releases spectrometry products for proteomics
Thermo Fisher Scientific has announced an exclusive license agreement with software firm MSAID for intelligent software that uses deep learning facilitated...

Thermo Fisher gets U.S. contract for COVID-19 sample collection
Thermo Fisher Scientific announced that it has received a contract from the U.S. government to provide highly specialized viral transport media for COVID-19...